The International Council on Infertility Information Dissemination, Inc

Outcome Based Reporting Expected to Garner Support for Insurance Coverage for IVF

Outcome Based Reporting System for Assisted Reproductive Technology (ART) Statistics is Expected to Garner Support for Insurance Coverage of IVF


INCIID (the International Council on Infertility Information Dissemination) announced that it is in the development stage of launching a new system for reporting in vitro fertilization (IVF) outcomes.


The new system, being developed by INCIID will accurately report all ART (assisted reproductive technology) cases undertaken by participating medical providers and the outcomes of each. The new project is expected to offer a cost-effective way for insurance companies to provide benefits for IVF and other assisted reproductive medical technology based on acceptable clinical outcomes.


“We believe that there are safe and effective ways for couples faced with infertility to conceive a child, and it is important for insurance to cover this type of treatment, thereby making it available to the millions of couples who are involuntarily childless,” explained Nancy P. Hemenway, Executive Director of INCIID (


As recent articles have pointed out (See “The Terrifying Truth about Fertility Drugs”, O Magazine, February 2004) the validity and enforceability of the current Centers for Disease Control and Prevention (CDC) and Society for Assisted Reproductive Technology (SART) system for reporting ART outcomes is questionable. The results of this government-endorsed reporting system (which is published annually on the CDC’s official web site) are largely self-generated by SART member-programs, with little or no oversight or regulation, making it possible to overstate success rates in some cases. The CDC and SART currently report IVF success rates solely on the basis of age. However many other factors, such as the number of prior IVF failures and the responsiveness of a woman’s ovaries to stimulation with fertility agents, may have a profound influence on outcome. Thus, the door is left open for programs to limit access to the “easier cases” so as to report higher overall IVF success rates.


INCIID believes its new system, by providing verifiable and reliable reporting of ART success rates with no room for manipulation will benefit the patient/consumer and encourage medical providers and insurance companies to offer effective treatments at a cost both insurance companies and the consumers can afford.


The InterNational Council on Infertility Information Dissemination is North America’s largest family-building organization. INCIID, a US based nonprofit, provides millions with immediate information and support on the diagnosis, treatment, and prevention of infertility and pregnancy loss.



CONTACT: Nancy P. Hemenway
(703) 379-9178





Learn the Facts, Dismiss the Myths, and
Find the Reproductive Resources that Help


INCIID (the International Council on Infertility Information Dissemination) applauds O Magazine and Barbara Seaman’s efforts (“The Terrifying Truth about Fertility Drugs”, February 2004) to inform the public about potential concerns in infertility treatment. INCIID ( has long-believed that the public needs more information, resources and support when making difficult decisions regarding fertility treatments.


In particular, INCIID agrees with Ms. Seaman regarding the lack of accountability in the way programs report their IVF statistics. The public must insist on a scrupulously-maintained and verifiable national system for IVF record-keeping. That is why INCIID has developed a new nationwide reporting system to provide the public with accurate, verifiable statistics on IVF outcomes.


Unfortunately, the remainder of the article was based on misleading information and unsubstantiated findings.

Sadly, Ms. Seaman leads her readers to the foregone conclusion that gonadotropin therapy increases a woman's risk of ovarian and breast cancers. Readers of O Magazine have a right to know that there is absolutely no scientific evidence to show a cause-and-effect relationship between gonadotropin therapy and these cancers.


Clomiphene citrate, a commonly used fertility drug (pill) is another matter altogether. Epidemiologic studies do suggest a possible increase in the incidence of ovarian cancer when this drug is administered every month for longer than a year. Clomiphene, unlike gonadotropins is a “synthetic “product derived from diethylstilbestrol (DES), a drug known to have caused vaginal carcinoma in the offspring of mothers who took it during pregnancy.

While Ms. Seaman’s anecdotal observations about Liz Tilberis and Gilda Radner’s medical struggles are poignant, they provide rather insensitive and misleading information for those who suffer from infertility. We at INCIID would like to correct some of the more significant distortions within the article;


*The article stated the drug Lupron can lead to bone loss (osteoporosis). This is true only if the drug is used for many months without the routinely prescribed precautions, such as low dose estrogen to prevent such bone loss.

*The author goes on to say gonadotropins (Pergonal, Follistim, Bravelle, Repronex) can cause Severe Ovarian Hyper Stimulation Syndrome (OHSS). This too, is true only if a woman who is hypersensitive to the drugs is treated with them indiscriminately. For decades, reproductive medicine programs have treated at-risk patients with these medications in a judicious, selective manner successfully taking precautions to prevent the life-endangering risks of OHSS.

* Some words about multiple pregnancy rates associated with infertility drugs; Often, in an attempt to optimize success rates, IVF programs transfer too many embryos. This increases the possibility of high-order multiple births [triplets or greater]. Multiple pregnancy and birth are hazardous to the mother’s health and associated with high risk of premature delivery as well as other severe complications that can prevail throughout the life of the offspring. Without responsible management of embryos transferred, insurance companies are likely to resist coverage for IVF procedures. We believe disincentives can be created, discouraging physicians from transferring too many embryos or conducting unmonitored fertility cycles resulting in multiple pregnancy.


Is IVF risk-free? Certainly not! No medical procedure is without risk. However, couples faced with making family-building decisions will make the best decisions when provided with accurate information provided with empathy and compassion. They need an advocate who will push for needed changes – like getting insurers to cover IVF. INCIID is doing just that.



Nancy P. Hemenway
INCIID Executive Director

The International Council on Infertility Information Dissemination, (INCIID---pronounced “inside”) is a Washington DC Metropolitan Area based US non-profit which, for the past decade, has helped millions of infertile couples explore their best family-building options. INCIID has brought together a group of internationally renowned fertility experts who ensure information disseminated through INCIID is accurate and reflects current diagnostic and treatment protocols.



Marilyn Seiger 
Kovak-Likly Communications 203-762-8833





Rancho Las Palmas, CA -- April 22, 2002 -- Results of clinical trials evaluating Ferring Pharmaceuticals' infertility treatments -- a human-derived follicle stimulating hormone (hFSH) and a purified human menopausal gonadotropin (hMG), which are currently under investigation -- were presented at the 50th Annual Pacific Coast Reproductive Society Meeting in Rancho Las Palmas, CA, April 17 to 21, 2002. Four clinical abstracts and two posters were presented.


"These new clinical studies reflect Ferring's commitment to broadening the existing body of knowledge in the field of infertility, while also providing meaningful data that reflect current treatment trends," said Wayne Anderson, president of Ferring Pharmaceuticals Inc. "As specialists in the development of human-derived hormone medications, we look forward to offering physicians even greater treatment flexibility when we receive approval of our new hFSH - the fourth addition to our family of human-derived hormones." Same Syringe Mixed Protocol with Diluent

Ferring's hFSH and purified hMG were tested to determine if the bioactivities of FSH and LH contained in the two treatments are altered after reconstituting them in the same diluent and mixing them in the same plastic syringe.

"This is the first time that FSH and hMG mixed in the same syringe has been tested using sophisticated bioassays," said Mahendra DeSilva, Ph.D., Ferring's manager of Professional Services. "Mixed protocols for ovarian stimulation are widely-used, and often combine FSH and hMG in the same syringe to decrease the number of daily injections. Once approved, infertility specialists will be able to mix Ferring's hFSH and purified hMG in the same syringe with the assurance that the bioactivity of FSH and LH remains unchanged."


Separate low, medium and high dose bioassays were performed in duplicate, comparing Ferring's hFSH, purified hMG and FSH and LH Reference Standards. The study demonstrated that Ferring's hFSH and purified hMG can be reconstituted in 0.9% sodium chloride and combined in the same syringe with no alterations in the bioactivity of FSH or LH.


Ferring's Purified hMG Comparative Study

Ferring's purified hMG was evaluated in a prospective, randomized, parallel group, open-label, multicenter study that compared purified hMG administered subcutaneously (SC) and intramuscularly (IM) to Repronex administered SC in patients undergoing in vitro fertilization. The primary measure of efficacy was the number of oocytes retrieved. Results were positive and were described in detail in posters presented at the meeting.


About Repronex and Ferring

Repronex is the only human menopausal gonadotropin (hMG) approved for both subcutaneous and intramuscular administration. It is also the most frequently prescribed hMG. Repronex, like all gonadotropins, is a potent substance capable of causing mild to severe adverse reactions, including OHSS (incidence of 3.5%), with or without pulmonary or vascular complications, in women undergoing therapy for infertility. Only physicians thoroughly familiar with infertility treatment, including the risk of multiple births and adverse reactions, should prescribe Repronex.


Ferring Pharmaceuticals Inc., headquartered in Tarrytown, NY, is part of the Ferring Group, a privately owned, international biopharmaceutical company that specializes in the research, development and commercialization of compounds in general and pediatric endocrinology, urology, gastroenterology, obstetrics/gynecology and infertility. For more information, call 1-888-337-7464 or visit the Ferring Web site at www.ferringusa.coma


Woman's World Magazine: Miracle in Cyberspace

Miracle in Cyberspace"
An article from Woman's World Magazine

It was nighttime in Fairfax County Va. When Nancy Hemenway switched on her computer. As the light from the screen bathed the darkened room in a glowing blue, she took a deep breath and typed in the keyword inferility.Dozens of messages, posted by others, flashed in front of her. All these women are like me, she thought. Tentatively, she typed: Can someone out there help me?

For years, Nancy's hopes of becoming a mother were alternately fanned and crushed. First, doctors couldn't explain why she didn't conceive. Fertility treatments worked, but she suffered one miscarriage after another. In her mourning, her husband David would hold her close and whisper: "Until the time is right, we have each other." The time has been right for years, she thought. Maybe the doctor is missing something.

Online, childless Nancy Hemenway found more than information-she found a friend who made her dream come true

As a teacher, Nancy used the computer for research, so she was familiar with online services. Maybe that's where I'll find what I'm looking for. I always pictured myself looking into a tiny face that [ooks lovingly back, she typed in that night. The next day, she logged on again and was stunned to find dozens of messages for her. You'll find many supportive women here, one read. We're like family, said another. She clicked on the next message-and stared at the screen in surprise. Your problem sounds like mine, a woman named Nancy Amicon had written. She went on to tell Nancy about a Chicago reproductive immunologist, Alan Beer, M.D. I'll send you information, she wrote. Can she really help? Nancy thought cautiously. But she alreadv felt buoyed by new hope. Days later, she pored over the packet her new friend had sent: Unexplained miscarriages may be an immunological problem, she read. A possible reason for all this misery! she thought. Thank you, Nancy typed to her friend. Fm sending this to my doctor. Well, what did you think?' she asked her doctor. "It doesn't apply to you," he said dismissively. How can you be sure? she thought. Let's see what Dr. Beer thinks and she dialed for an appointment

. The office responded with a list of blood tests she and David should have. I have a good feeling about this, she thought. A few weeks later, she came home to a message on her answering machine: 'This is Dr. Beer. I think I can help you." Do I dare to hope? she thought. Excitedly, Nancy and David flew to Chicago. They listened as Dr. Beer explained: 'A woman produces antibodies to keep her immune system from rejecting a baby. But since you and David are a very close tissue match, your baby is a close match too-close enough to fool Nancy's body into not producing the necessary blocking antibodies. But not close enough to keep her from rejecting it." That's why I miscarry, Nancy thought with astonishment.

Nancy began treatment, which included a drug that helps transplant recipients accept donor organs. That meant daily self-injections in her abdomen now and throughout her pregnancy. But it's a small price to pay, she thought, wincing with each shot. Dr. Beer said it could take over a year, but Nancy was more hopeful. Yet months passed. Be patient, her online friends wrote. Her friend Nancy Amicon wanted to deliver her encouragement in person. She's driving down from Pennsylvania to meet us!" Nancy told David. But when Nancy opened the door, she found that her friend was not alone. In her arms was a beautiful little girl. "This is Paige, my little miracle," her friend said. "Your miracle will happen too." But every trip to the lab for a pregnancy test was followed by a heartbreaking phone call. "Not yet,' the lab nurse would tell her.

Then one day Nancy answered the phone to hear the lab staff cheer: "You're pregnant!" Laughing and crying, she called David. 'We're going to have a baby!' she gushed, but even as she spoke the words, she felt fear. I've been pregnant before ... At five weeks, Nancy typed: We saw the baby's heartbeat on the ultrasound. At 20 weeks: I felt her kick! As the weeks passed,she rejoiced with the baby's every move. When she entered her seventh month, the doctor told her that she should feel the baby kick about every four hours. And as weeks passed, no matter what she was doing, she marked the baby's every motion. But in her thirty-seventh week, she fearfully waited as the fourth hour passed without any movement. Then the fifth. Worry nearly paralyzing her, David rushed her to the hospital. 'I just can't lose this baby," she sobbed as the doctor examined her. 'Let's induce labor," he said. "This baby is ready to be born, so let's not take any chances."

Nancy prayed as the epidural for her C-section was administered. And when she heard Zoes first cry, she turned to David, saying, "Is it a dream?" Two days later, Nancy was home, typing between feedings:
She's beautiful, with a head of dark hair I couldn't have gotten through this without all of you. 


Parents, Nancy and David Hemenway at a reunion of
other couples and their babies.

Recently, Nancy sat in her pediatrician's waiting room with nine-month-old Zoë in her arms. Talk between the mothers turned to labor and delivery. Where was your baby born?" one woman asked Nancy. Nancy paused, then said in all seriousness: "Cyberspace."

Zoe enjoying a leisurely ride in the family car.

Even though she's now a mom, Nancy Hemenway remains active in helping infertile couples. She founded the InterNationalCouncil on Infertility Information Dissemination (INCIID pronounced "inside"), available through the Internet. If you're online, their World Wide Web address is

EEOC on Infertility


FOR IMMEDIATE RELEASE                                                  CONTACT

                                                                                            Elizabeth Grossman

                                                                                            (917) 509-8314


NEW YORK --- Judge Joanna Seybert has approved the entry of a Consent Decree providing that a Long Island employer will pay $135,000 to a former employee for damages she suffered when they terminated her rather than allowing her to continue infertility treatments.

The United States Equal Employment Opportunity Commission filed a lawsuit in the U.S. District Court for the Eastern District of New York agains the East Northport Residential Health Care Facility Inc. doing business as Huntington Hills Center for Health and Rehabilitation, a facility in Melville that provides specialized residential health care services. The EEOC complaint alleged that Huntington Hills discriminated against its employees by terminating an employee rather than accommodate her need to have three days off to complete infertility treatments, in violation of Title I of the Americans with Disabilities Act, the ADA. Subsequently, the parties filed the Consent Decree in which Huntington Hills, while not assuming liability for improper or illegal actions, agreed to compensate the employee $135,000 for back pay and compensatory damages. The Consent Decree also provides that Huntington Hills will provide training to all its management and staff regarding their obligations and rights under the ADA and will take appropriate corrective actions in administering its employee policies.

The EEOC enforces Title VII of the Civil Rights Act of 1961, as amended, which prohibits employment discrimination based on race, color, religion, sex or national origin; the Age Discrimination in Employment Act; the Equal Pay Act; prohibitions against discrimination affecting individuals with disabilities in the federal sector; sections of the Civil Rights Act of 1991; and Title I of the Americans with Disabilities Act, which prohibits discrimination against people with disabilities in the private sector and state and local governments.




ASRM Statement on Risk of Cancer

Embargoed For Release:                                                  CONTACT: 
January 24, 2002                                                                  Eleanor Nicoll at 202/863-2439,

                                                                                                  Sean Tipton at 202/863-2494 or             



ASRM Statement on Risk of Cancer 
Associated with Fertility Drugs


Attributable to Robert Rebar, MD
ASRM Associate Executive Director



From time to time, media reports will surface sounding the warning that drugs taken to induce ovulation cause cancer. While one study found a connection between the incidence of ovarian cancer and repetitive treatment cycles (more than 12), using a particular drug (clomiphene citrate), more recent research indicates that patients taking ovulation-inducing drugs face no greater cancer risk than the general population.

In addition, some patients may have underlying conditions, perhaps related to their infertility, that increase their risks of developing cancer. Exposure to environmental toxins, cigarette smoking, inadequate nutrition, and unhealthy body weight can contribute to difficulties conceiving, as well as increased cancer risk. 

The Practice Committee of the ASRM evaluates new research as it appears and issues reports containing its conclusions and recommendations for safe and effective treatment. Since questions remain about long-term consequences of the use of ovulation-inducing drugs, the Practice Committee recommends that physicians take a conservative stance and caution their patients that the use of certain fertility drugs may increase their lifetime risk of ovarian tumors. 

For further information, see Practice Committee Reports on ASRM's web-site. 


  • Repetitive Oocyte Donation, November 2000
  • Induction of Ovarian Follicle Development and Ovulation With Exogenous Gonadotropins,June 1998


ASRM, founded in 1944, has more than 8,500 members who are devoted to advancing knowledge and expertise in reproductive medicine and biology. ASRM-affiliate societies include the Society of Reproductive Surgeons, the Society for Reproductive Endocrinology and Infertility, the Society for Male Reproduction and Urology, and the Society for Assisted Reproductive Technology.





Embargoed For Release:                                                  CONTACT: 
January 11, 2001                                                                  Eleanor Nicoll at 202/863-2439,

                                                                                                  Sean Tipton at 202/863-2494 or             



Vol. 77, No. 1, January 2002 



Mother Nature may be impartial but that doesn't mean she's fair. For about half a century, men have been able to freeze their sperm quite successfully. Whether for donation, or to preserve future fertility in the face of disease and treatment, the option of putting a few vials into storage is fairly easy, available throughout the developed world, and not prohibitively expensive. The same is not true for women who may wish to freeze their eggs. Eggs don't survive freezing very well. 

Searching for a way to increase the chances of survival for frozen eggs, doctors and scientists at Massachusetts General Hospital and Harvard Medical School tried a new technique for freezing eggs. 

Freezing methods involve the use of various chemicals- cryoprotectants- in different concentrations depending on speed of the freezing. Different types of cells react differently to the procedure. It turns out that egg cells are particularly delicate, suffering rupture of the cell membrane and damage to internal structures when frozen. (Embryos, however, freeze very well.) While traditional cryopreservation methods use sugars outside the frozen cells, studies on types of cells other than eggs have shown that, to enhance protection, the sugars should also be present inside the cells.

Using IVF patients' donated eggs that had failed to fertilize or mature, Dr. Eroglu and his colleagues compared the results of three freezing protocols. The cryoprotectant they used was trehalose, a type of sugar found in high concentrations inside the cells of many anhydrobiotic organisms that, in the wild, survive extreme conditions of dehydration. One set of eggs was frozen, as a control, without trehalose, another had trehalose as a component of the extra-cellular medium, and the third set had a small amount of trehalose (comparable to the amount found within the cells of anhydrobiotic organisms) injected intracellularly and was also frozen in trehalose-containing medium.

Eggs preserved according to the three protocols were frozen, thawed and examined for survival by evaluating their appearance and membrane integrity. In the control group, only 13% of eggs survived freezing. In the group frozen in trehalose-containing medium, 22% survived. However, the group of eggs that were both injected with trehalose and frozen in medium containing the sugar exhibited a much greater survival rate: 63% at -15ºC. This clearly indicates that intracellular trehalose has a beneficial effect on freezing human eggs.

"The use of intracellular sugars for freezing eggs is very promising. We need to do more work to find a solution to this problem. Young women facing treatment for cancer or other diseases shouldn't at the same time have to face the end of their dreams to have a family," commented William Keye, Jr., MD, President of the ASRM.

ASRM, founded in 1944, has more than 8,500 members who are devoted to advancing knowledge and expertise in reproductive medicine and biology. ASRM-affiliate societies include the Society of Reproductive Surgeons, the Society for Reproductive Endocrinology and Infertility, the Society for Male Reproduction and Urology, and the Society for Assisted Reproductive Technology.


# # #

(Eroglu, et al., "Beneficial effect of microinjected trehalose on the cryosurvival of human oocytes," Fertility & Sterility, Vol.77, No.1, January 2002) 

Editors Note: Fertility and Sterility is now available on-line.





More Than 30,000 Babies Born in ’99 as a Result of ART Procedures

Embargoed For Release:                                                                  Embargoed For Release: 
December 14, 2001                                                                             December 14, 2001         




More Than 30,000 Babies Born in ’99 as a Result of ART Procedures

More than 30,000 babies were born in 1999 as the result of assisted reproductive technology (ART) according to the latest annual report on fertility clinic success.

According to the new report, 370 clinics nationwide performed 86,822 ART cycles where human eggs are fertilized with sperm in a laboratory and transferred into a woman’s uterus. These procedures resulted in the birth of 30,285 babies. Slightly over 25% of the ART cycles resulted in a birth of a baby for women using their own eggs. This figure is an improvement over the 1998 rate. In 1995, the first year the CDC reported the data, the overall success rate was below 20%.

“We are very proud of our role in bringing this information to the public,” said Jamie Grifo, MD, PhD, President of the Society for Assisted Reproductive Technology (SART). “Infertility clinics in the United States are virtually the only medical facilities in the world that report their medical outcomes in this comprehensive way. Our members work very hard to collect this data, and use it to improve treatments for their patients. It is a major undertaking for the SART member clinics to assist us in collecting this information, and we appreciate all the hard work that goes into it.”

William Keye, MD, President of the American Society for Reproductive Medicine (ASRM) added, “Information in this report will help patients as they struggle with their infertility.” He urged consumers to be careful in how they use the data however. “Success rates depend on many factors, including the characteristics of the patients they are treating. Individual patients should work with their physicians to find the right facility for them.”

The 1999 report was prepared jointly by the CDC, the American Society for Reproductive Medicine (ASRM), the Society for Assisted Reproductive Technology (SART), and RESOLVE, a national consumer organization that helps people with infertility issues. The full report is available on the CDC Web site at: or printed copies can be ordered by calling CDC at (770) 488-5372.

ASRM, founded in 1944, has more than 8,500 members who are devoted to advancing knowledge and expertise in reproductive medicine and biology. ASRM-affiliate societies include the Society of Reproductive Surgeons, the Society for Reproductive Endocrinology and Infertility, the Society for Male Reproduction and Urology, and the Society for Assisted Reproductive Technology.



WASH, D.C. (Oct.28, 1998) – In a 3-0 decision, the United States Court of Appeals for the District of Columbia ruled in favor of Ferring Pharmaceuticals, Inc., vacating a preliminary injuction brought by Serono Laboratories, Inc., that attempted to block the introduction of Repronex TM
an infertility drug.


In the opinion for the Court filed by Circuit Judge Garland, he states, "In this case we consider the validity of the district court order, preliminarily enjoining approval by the Food and Drug Administration (FDA) of a generic drug, that was issued at the behest of the manufacturer of the competing brand drug. We previously stayed the preliminary injuction pending our resolution of this appeal. Because we find the plaintiff has not satisfied the standards for preliminary injuction, and in particular has not shown a likelihood of success on the merits, we now vacate the injunction."


"The lawsuit by Serono did not stop us from marketing Repronex, and bringing to patients this much needed, substantially less expensive equivalent to Pergonal®," says Wayne Anderson, President of Ferring Pharmaceuticals, Inc. "The Court of Appeals ruling confirms our longstanding view that this suit was totally without merit. In just over a year, Repronex has become one of the most frequently prescribed human menopausal gonadatropins, demonstrating the need for cost-effective alternatives for the treatment of infertility."


Contact: Ellen Kovak
(203) 762-8833


# # #



Ferring Pharmaceuticals Inc., 120 White Plains Road, Suite400, Tarrytown, NY 10591
Telephone: (914) 333-8900 TeleFax: (914) 631-7992


Press Release: Study Shows Increased Orgasms and Decreased Sexual Pain after Manual Physical Therapy Technique

Study Shows Increased Orgasms and Decreased
Sexual Pain after Manual Physical Therapy Technique


GAINESVILLE, FL, December 14, 2004 – In a study published today in Medscape General Medicine, Ob/Gyn & Women's Health, researchers reported that a manual physical therapy technique is highly effective in increasing orgasm intensity and frequency and reducing painful intercourse in women.


The therapy, known as the Wurn Technique®, is a new, patent protected series of manual physical therapy and massage techniques designed to reduce adhesions and mechanical factors that cause pain or dysfunction. No drugs or surgery are involved. (


Study participants were 23 women who reported painful intercourse and/or difficulty or inability to orgasm. According to the study, the therapy significantly increased orgasm in 56% and reduced intercourse pain in 96% of the women. Statistically significant improvements were noted in all six major areas (desire [libido], arousal, lubrication, orgasm, satisfaction, and pain) on a standardized test of female sexual dysfunction.


Co-developer, Belinda Wurn, PT, says, "Adhesions can form anywhere in the female reproductive tract, decreasing sensation and causing pain. Our therapy frees the tissues from these adhesive constraints, restoring normal function and allowing women to return to a healthy sex life."


The study is the third to be published on the Wurn Technique® in Medscape General Medicine, Ob/Gyn & Women's Health this year. Two prior studies, published in June, reported the therapy's effectiveness in helping infertile women to conceive. In the first study, natural pregnancy occurred in 71% of infertile women within one year of treatment. The second study showed that women who used the therapy within 15 months prior to in vitro fertilization (IVF) increased their chances for IVF pregnancy by 63%.



FOR RELEASE ON DECEMBER 14, 2004                   

Anna Waldthausen at 917.403.6200

Clear Passage Therapies® has clinics in Gainesville, FL, Toledo, OH, Bethesda, MD and plans to open clinics in other major US cities throughout 2005. More information is available at or toll free at 1-866-222-9437.


# # #